Tarsus Pharmaceuticals Q1 2023 Earnings Report $51.74 +1.09 (+2.15%) As of 03/28/2025 04:00 PM Eastern Earnings HistoryForecast Tarsus Pharmaceuticals EPS ResultsActual EPS-$0.88Consensus EPS -$0.95Beat/MissBeat by +$0.07One Year Ago EPSN/ATarsus Pharmaceuticals Revenue ResultsActual Revenue$2.50 millionExpected Revenue$3.33 millionBeat/MissMissed by -$830.00 thousandYoY Revenue GrowthN/ATarsus Pharmaceuticals Announcement DetailsQuarterQ1 2023Date5/9/2023TimeN/AConference Call ResourcesPress ReleaseTARS Earnings HistoryPowered by Remove Ads Tarsus Pharmaceuticals Earnings HeadlinesAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Opthea Limited Sponsored ADR (OPT) and Larimar Therapeutics (LRMR)March 25, 2025 | markets.businessinsider.comTarsus Pharmaceuticals 2.809M share Spot Secondary priced at $44.50March 13, 2025 | markets.businessinsider.comElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the federal government. And that's creating a huge buying opportunity for the stocks involved. Put simply, under Elon's watchful eye, the U.S. government is rapidly adopting AI technology. And that's sending certain stocks soaring higher.March 30, 2025 | Altimetry (Ad)Tarsus prices $125M stock offeringMarch 13, 2025 | msn.comTarsus Pharmaceuticals announces $100M common stock offeringMarch 12, 2025 | markets.businessinsider.comTarsus Announces Pricing of Upsized $125.0 Million Public OfferingMarch 12, 2025 | globenewswire.comSee More Tarsus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tarsus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tarsus Pharmaceuticals and other key companies, straight to your email. Email Address About Tarsus PharmaceuticalsTarsus Pharmaceuticals (NASDAQ:TARS), a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.View Tarsus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
